Compare RL & WAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RL | WAT |
|---|---|---|
| Founded | 1967 | 1958 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Laboratory Analytical Instruments |
| Sector | Consumer Discretionary | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.5B | 22.5B |
| IPO Year | 1997 | 1995 |
| Metric | RL | WAT |
|---|---|---|
| Price | $357.87 | $386.39 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 14 | 15 |
| Target Price | $376.46 | ★ $390.67 |
| AVG Volume (30 Days) | ★ 708.7K | 543.5K |
| Earning Date | 02-05-2026 | 02-11-2026 |
| Dividend Yield | ★ 1.02% | N/A |
| EPS Growth | ★ 28.75 | 3.82 |
| EPS | ★ 13.54 | 10.88 |
| Revenue | ★ $7,570,600,000.00 | $3,105,638,000.00 |
| Revenue This Year | $12.94 | $7.96 |
| Revenue Next Year | $5.02 | $6.32 |
| P/E Ratio | ★ $26.45 | $35.50 |
| Revenue Growth | ★ 12.32 | 6.90 |
| 52 Week Low | $176.61 | $275.05 |
| 52 Week High | $380.00 | $423.56 |
| Indicator | RL | WAT |
|---|---|---|
| Relative Strength Index (RSI) | 51.43 | 52.59 |
| Support Level | $360.34 | $372.17 |
| Resistance Level | $380.00 | $385.69 |
| Average True Range (ATR) | 8.99 | 8.05 |
| MACD | -1.99 | -1.75 |
| Stochastic Oscillator | 32.53 | 51.95 |
Founded by designer Ralph Lauren (current executive chairman and chief creative officer) in 1967 in New York City, Ralph Lauren Corp. designs, markets, and distributes lifestyle merchandise in North America, Europe, and Asia. Best known for its iconic polo shirts, its products also include other types of apparel, footwear, eyewear, jewelry, handbags, home goods, and fragrances. The company's brands include Ralph Lauren Collection, Polo Ralph Lauren, and Lauren Ralph Lauren. Distribution channels for Ralph Lauren include wholesale (department stores and specialty stores), retail (company-owned retail stores and e-commerce), and licensing.
Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2024, Waters generated 58% from biopharmaceutical customers, 31% from industrial clients, and 11% from academic/government institutions. In early 2026, Waters plans to merge with BD's life science and diagnostics business, which will substantially change those concentrations. Waters will wind up with more concentration in diagnostics (versus none now) and discovery-related life science tools.